Understanding how a specific protein affects brain damage in Alzheimer's disease

Deciphering the role of CX3CR1 in Modulating Mechanisms of Amyloid driven Neurodegeneration in Alzheimer's Disease

['FUNDING_R01'] · INDIANA UNIVERSITY INDIANAPOLIS · NIH-10875708

This study is looking at how a protein called CX3CR1 affects the brain's ability to deal with harmful amyloid plaques related to Alzheimer's disease, with the hope of finding new ways to help people with this condition.

Quick facts

Phase['FUNDING_R01']
Study typeNih_funding
SexAll
SponsorINDIANA UNIVERSITY INDIANAPOLIS (nih funded)
Locations1 site (INDIANAPOLIS, UNITED STATES)
Trial IDNIH-10875708 on ClinicalTrials.gov

What this research studies

This research investigates the role of the CX3CR1 protein in the brain's response to amyloid plaques, which are linked to Alzheimer's disease. It focuses on how changes in CX3CR1 signaling may influence the activation of microglial cells, the brain's immune responders, and their ability to clear toxic substances. By examining the relationship between CX3CR1 and neurodegeneration, the study aims to uncover new insights that could lead to better therapeutic strategies for Alzheimer's patients.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those at high risk for developing it.

Not a fit: Patients with other forms of dementia unrelated to amyloid pathology may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to new treatments that improve brain health and slow the progression of Alzheimer's disease.

How similar studies have performed: Previous research has shown promising results in understanding the role of microglial activation in neurodegeneration, suggesting that this approach could yield valuable insights.

Where this research is happening

INDIANAPOLIS, UNITED STATES

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.

View on NIH RePORTER →

Conditions: Alzheimer disease dementia, Alzheimer syndrome

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.